Schizophrenia Research Forum - A Catalyst for Creative Thinking
Home Your Profile Become a Member/Get Newsletter Contact Us
What's New
Recent Updates
SRF Papers
Current Papers
Search All Papers
Search Comments
News
Research News
Forums
Current Hypotheses
Idea Lab
Online Discussions
Virtual Conferences
Interviews
Tech Corner
Resources
What We Know
SchizophreniaGene
Animal Models
Drugs in Trials
Research Tools
Grants
Jobs
Conferences
Journals
Community Calendar
General Information
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
History
SRF Team
Advisory Board
Support Us
How to Cite
Fan (E)Mail
The Schizophrenia Research Forum web site is sponsored by NARSAD, the Brain and Behavior Research Fund, and was created with funding from the U.S. National Institute of Mental Health.
Printable version  
SZGene - Gene overview of all published SZ-association studies for DTNBP1    
Back Search Methods Disclaimer Credits
 Gene: DTNBP1  (SDY; DBND; HPS7; My031; FLJ30031; MGC20210)  Entrez Gene
 Protein: dystrobrevin binding protein 1  (dysbindin)  ProteinLink
 Chromosome: 6   (View: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  X  Y  MT)
 Status: Updated 21 October 2010
Meta-Analysis
1. Case-Control Studies (by ethnic group)
      SZ Cases Normal Controls    
Study Population Source # Polys # Subjects
(% women)
DX Onset Age
(range)
Age
(range)
# Subjects
(% women)
Age
(range)
Result Comment
 Caucasian
Bakker, 2006
Netherlands CL  4  (detail)  308
(-)
IV--580
(-)
-Negative
Betcheva, 2009
Bulgaria (I) CL  13  (detail)  185
(-)
IV--184
(-)
-Trend
Betcheva, 2009
Bulgaria (II) CL  1  (detail)  70
(-)
IV--372
(-)
-Negative
Datta, 2007
UK CL  8  (detail)  450
(-)
RDC--450
(-)
-Negative
Dutt, 2009
UK, Ireland CL  2  (detail)  83
(-)
IV--57
(-)
-Negative
Dwyer, 2009
UK CL  7  (detail)  669
(32%)
IV--710
(33%)
-Negative
Fallgatter, 2010
Germany CL  7  (detail)  44
(50%)
IV-36.3 + 9.6
(-)
48
(54%)
26.5 + 7.2
(19-63)
n.a.
Funke, 2004
USA (I) CL  6  (detail)  196
(-)
IV--467
(52%)
39.3
(-)
Positive
Holliday, 2006
Australia CL  15  (detail)  194
(-)
M--180
(-)
-Negative
Jonsson, 2009
Denmark, Norway, Sweden CL  11  (detail)  837
(42%)
M26.5
(-)
45.7
(-)
1473
(42%)
44.1
(-)
Negative
Li, 2005
UK (Scotland) CL  11  (detail)  580
(28%)
M--620
(43%)
-Negative
Morris, 2003
Ireland CL  8  (detail)  219
(-)
IIIR--231
(-)
-Negative
Morris, 2007
Overlaps with
Morris, 2003
CL  2  (detail)  373
(-)
IV--812
(-)
-n.a.
Morris, 2007
Overlaps with
Williams, 2004
CL  1  (detail)  373
(-)
IV--812
(-)
-n.a.
Pedrosa, 2006
USA (II) CL  1  (detail)  172
(-)
M--165
(-)
-Negative
Peters, 2008
Australia CL  37  (detail)  336
(20%)
M--172
(41%)
-Negative
Rethelyi, 2009
Hungary CL  4  (detail)  280
(54%)
IV28.6
(-)
37.6
(-)
230
(57%)
39.9
(-)
Positive
Riley, 2009
Ireland, UK CL  9  (detail)  1021
(32%)
IIIR--626
(45%)
-Positive
Sanders, 2008
USA, Australia CL  38  (detail)  1870
(31%)
IV--2002
(53%)
-Negative
Strohmaier, 2010
Germany CL  35  (detail)  634
(45%)
IV-38.5 + 11.7
(-)
776
(43%)
45.5 + 13.5
(-)
Negative
Tosato, 2007
Italy CO  11  (detail)  80
(49%)
10-42
(-)
106
(47%)
38
(-)
Positive
Van Den Bogaert, 2003
Overlaps with
Strohmaier, 2010 (Germany)
CL  5  (detail)  418
(52%)
IV--285
(40%)
-Negative
Van Den Bogaert, 2003
Poland CL  5  (detail)  294
(41%)
IV--113
(63%)
-Negative
Van Den Bogaert, 2003
Sweden CL  5  (detail)  142
(38%)
IV--272
(45%)
-Positive
Vilella, 2007
Spain PO  11  (detail)  589
(31%)
IV--615
(48%)
-Positive
Voisey, 2010
Australia CL  12  (detail)  160
(14%)
IV-36.2 + 12.1
(-)
250
(41%)
36.8 + 12.8
(-)
Positive
Williams, 2004
Overlaps with
Morris, 2003
CL  2  (detail)  219
(101%)
IIIR25.2 + 12.4
(-)
46 + 8.5
(-)
231
(-)
-Positive
Williams, 2004
UK, Ireland CL  20  (detail)  708
(31%)
IV23.6 + 7.7
(-)
41.8 + 13.5
(-)
711
(33%)
-Positive
Williams, 2004
Ireland (II) CL  1  (detail)  219
(-)
IIIR25.2 + 12.4
(-)
46 + 8.5
(-)
231
(-)
-Positive
Wood, 2006
USA CL  15  (detail)  311
(-)
IV--291
(-)
-Negative
Zuo, 2009
USA (I) CL  6  (detail)  235
(-)
IIIR--298
(-)
-Positive
 African Descent
Funke, 2004
USA (II) CL  6  (detail)  184
(-)
IV--74
(59%)
31.9
(-)
Positive
Pedrosa, 2006
USA (I) CL  1  (detail)  152
(-)
M--129
(-)
-Negative
Zuo, 2009
USA (II) CL  6  (detail)  82
(-)
IIIR--48
(-)
-Trend
 Asian
Hashimoto, 2009
Japan CL  1  (detail)  70
(39%)
IV24.8
(-)
45.1
(-)
165
(67%)
37.3
(-)
n.a.
Hokyo, 2010
Japan CL  1  (detail)  407
(42%)
IV-54.7
(-)
384
(64%)
40.1
(-)
Negative
Joo, 2006
Korea CL  5  (detail)  194
(35%)
IV22.7 + 5.7
(-)
35 + 6.2
(-)
351
(50%)
25.9 + 6.4
(-)
Negative
Numakawa, 2004
Japan CL  6  (detail)  670
(49%)
IV-44.2 + 14.6
(-)
588
(51%)
36.2 + 12.4
(-)
Positive
Pae, 2009
Korea CL  4  (detail)  908
(49%)
M-33.7
(-)
601
(49%)
38.9
(-)
Positive
Tochigi, 2006
Japan CL  12  (detail)  314
(44%)
IV-46.3 + 14.9
(-)
314
(44%)
37.6 + 11.3
(-)
Positive
 Hispanic
Funke, 2004
USA (III) CL  6  (detail)  41
(-)
IV--32
(41%)
32.9
(-)
Negative
 Other/Mixed
Pedrosa, 2006
USA (I+II) CL  3  (detail)  324
(-)
M--294
(-)
-Negative
Zinkstok, 2007
Netherlands and Other CL  7  (detail)  76
(13%)
IV-21.5 + 2.9
(-)
31
(26%)
21.5 + 3.1
(-)
Negative
Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.
2. Family-Based Studies (by ethnic group)
      Affecteds Unaffecteds    
Study Population # Polys # Families # Subjects
(% women)
DX Onset Age
(range)
Age
(range)
# Subjects
(% women)
Age
(range)
Result Comment
 Caucasian
Hall, 2004
South Africa  5  (detail)  233-IV----Negative
Hall, 2004
USA  5  (detail)  210-IV----Negative
Holliday, 2006
Australia  15  (detail)  41114
(-)
M--135
(-)
-Negative
Kirov, 2004
Bulgaria  8  (detail)  488488
(48%)
IV-33.1 + 8.2
(-)
976
(50%)
59.9 + 9.2
(-)
Positive
Straub, 2002
Ireland  12  (detail)  270-IIIR----Positive
Strohmaier, 2010
Overlaps with
Schwab, 2003 (Germany)
 35  (detail)  180-IV----Negative
Turunen, 2007
Finland  17  (detail)  441865
(39%)
IV--999
(-)
-Negative
Van Den Oord, 2003
Ireland  14  (detail)  268-IIIR----Positive
Wessman, 2009
Re-analysis of Turunen, 2007  15  (detail)  292-IV----n.a.
 Asian
Li, 2005
China  8  (detail)  638810
(45%)
M--620
(-)
-Positive
Liu, 2007
Taiwan  9  (detail)  6931487
(39%)
IV22.9 + 6.8
(-)
36 + 9.6
(-)
1300
(52%)
55.7 + 15.4
(-)
Negative
Tang, 2003
China  7  (detail)  233233
(44%)
IIIR-22.8 + 0.5
(-)
466
(50%)
-Positive
 Other/Mixed
De Luca, 2005
Canada  3  (detail)  11-IV----Trend
Duan, 2007
USA  26  (detail)  136319
(-)
IIIR--463
(-)
-Positive
Fallin, 2005
USA  16  (detail)  263274
(26%)
IV19.5 + 4.5
(-)
-548
(50%)
-Positive
Holliday, 2006
India  15  (detail)  197329
(-)
M--339
(-)
-Negative
Schwab, 2003
Mixed  6  (detail)  203281
(-)
IV----Positive
Zinkstok, 2007
Overlaps with
Zinkstok, 2007
 7  (detail)   76
(13%)
IV-21.5 + 2.9
(-)
31
(58%)
22.8 + 3.8
(-)
n.a.
Zinkstok, 2007
Netherlands and Other  7  (detail)  5252
(-)
IV----Negative
Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.
Source:  Source of case population -> “CL” (clinic-based), “PO” (population-based), or “CO” (community-based).
# Polys:  Number of polymorphisms tested per gene and per sample.
Onset Age and Age:  Mean or median age at onset or examination, respectively.
DX:  Criteria used to determine SZ diagnosis ->  "IIIR"(DSM-IIIR), "IV" (DSM-IV), "9" (ICD-9), "10" (ICD-10), "M" (Mixed), "RDC" (Research Diagnostic Criteria), "U" (Unknown).
Result:  Overall conclusion reached by authors of the original publication (“positive” usually indicates significant (P<0.05) association in at least one of the performed analyses, and “negative” indicates no evidence for significant association, while “trend” indicates results in between).
(-) :  Either no data provided or in case of overlap, data included in original study.
SZGene Recent Updates
SZGene Stats
Studies: 1727
Genes: 1008
Polymorphisms: 8788
Meta-analyses: 287
ALSGene
AlzGene
MSGene
PDGene
SZGene
An up-to-date collection of all published genetic association studies.
SRF News
SRF Comments
Text Size
Reset Text Size
Email this pageEmail this page

Share/Bookmark
Research Participants
Collaborators
Copyright © 2005-2014 Schizophrenia Research Forum Privacy Policy Disclaimer Disclosure Copyright